PEG-话题@MedSci

#PEG#

56篇内容 | 2086人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1533504, encodeId=f0da153350416, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, objectType=article, longId=186805, objectId=c58218680512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58218680512, replyNumber=0, likeNumber=55, createdTime=2020-01-29, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58218680512, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c58218680512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533503, encodeId=e6e81533503e6, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=53, createdTime=2020-01-10, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533502, encodeId=6dfd15335029e, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败, objectType=article, longId=181646, objectId=23b918164627, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b918164627, replyNumber=0, likeNumber=68, createdTime=2019-10-22, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b918164627, moduleTitle=礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b918164627)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533501, encodeId=c71e1533501e2, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, objectType=article, longId=181451, objectId=7dae1814517d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dae1814517d, replyNumber=0, likeNumber=93, createdTime=2019-10-19, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dae1814517d, moduleTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dae1814517d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533500, encodeId=fd0a1533500ac, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复, objectType=article, longId=180495, objectId=350f180495e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=350f180495e8, replyNumber=0, likeNumber=61, createdTime=2019-10-05, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=350f180495e8, moduleTitle=Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=350f180495e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533499, encodeId=849e15334995b, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, objectType=article, longId=180124, objectId=a26018012453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26018012453, replyNumber=0, likeNumber=60, createdTime=2019-09-28, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26018012453, moduleTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a26018012453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533498, encodeId=b6821533498ae, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用, objectType=article, longId=168017, objectId=08a016801e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a016801e31, replyNumber=0, likeNumber=68, createdTime=2019-06-12, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a016801e31, moduleTitle=Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a016801e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533497, encodeId=e2e7153349eef, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=42, createdTime=2019-06-04, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533496, encodeId=e76b15334963e, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Tissue Eng Part A：纳米图案化的PEG-GelMA-HA水凝胶增强牙髓干细胞的软骨形成分化, objectType=article, longId=166405, objectId=7c1a16640589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c1a16640589, replyNumber=0, likeNumber=43, createdTime=2019-05-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c1a16640589, moduleTitle=Tissue Eng Part A：纳米图案化的PEG-GelMA-HA水凝胶增强牙髓干细胞的软骨形成分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c1a16640589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533495, encodeId=1256153349531, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, objectType=article, longId=163805, objectId=7958163805a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7958163805a9, replyNumber=0, likeNumber=0, createdTime=2019-04-09, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7958163805a9, moduleTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7958163805a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533494, encodeId=dc2c153349483, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, objectType=article, longId=161663, objectId=6e94161663bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e94161663bc, replyNumber=0, likeNumber=80, createdTime=2019-03-06, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e94161663bc, moduleTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e94161663bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533493, encodeId=6c76153349323, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例, objectType=article, longId=161446, objectId=d491161446de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d491161446de, replyNumber=0, likeNumber=84, createdTime=2019-03-02, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d491161446de, moduleTitle=DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d491161446de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533492, encodeId=67381533492e5, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, objectType=article, longId=160531, objectId=d64716053136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64716053136, replyNumber=0, likeNumber=66, createdTime=2019-02-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64716053136, moduleTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64716053136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533491, encodeId=87001533491e0, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据, objectType=article, longId=159195, objectId=33e315919506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e315919506, replyNumber=0, likeNumber=77, createdTime=2019-01-31, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e315919506, moduleTitle=第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e315919506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533490, encodeId=117915334904e, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, objectType=article, longId=156635, objectId=3f5e156635a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f5e156635a8, replyNumber=0, likeNumber=104, createdTime=2018-12-27, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f5e156635a8, moduleTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f5e156635a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533489, encodeId=d35a1533489af, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=【临床治愈，一生一试】PegIFNα-2a助乙肝患者获得最佳治疗目标, objectType=article, longId=155029, objectId=3e501550291a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e501550291a, replyNumber=0, likeNumber=90, createdTime=2018-12-05, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e501550291a, moduleTitle=【临床治愈，一生一试】PegIFNα-2a助乙肝患者获得最佳治疗目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e501550291a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533488, encodeId=b5e0153348817, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=2018 APEG共识指南：儿童和青少年应用双磷酸盐治疗, objectType=article, longId=132082, objectId=bbc6132082e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc6132082e5, replyNumber=0, likeNumber=34, createdTime=2018-03-12, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc6132082e5, moduleTitle=2018 APEG共识指南：儿童和青少年应用双磷酸盐治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc6132082e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533487, encodeId=c712153348eb4, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Int J Nanomed：oMCN@PEG可作为高效抗癌药物递送载体使用, objectType=article, longId=122223, objectId=e119122223f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e119122223f6, replyNumber=0, likeNumber=61, createdTime=2017-12-05, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e119122223f6, moduleTitle=Int J Nanomed：oMCN@PEG可作为高效抗癌药物递送载体使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e119122223f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533486, encodeId=d3661533486a6, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Oncol Lett：LncRNA PEG10过表达可促进鳞状细胞癌的进展, objectType=article, longId=114883, objectId=4d361148838d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d361148838d, replyNumber=0, likeNumber=75, createdTime=2017-10-01, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d361148838d, moduleTitle=Oncol Lett：LncRNA PEG10过表达可促进鳞状细胞癌的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d361148838d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533485, encodeId=eb8a15334858c, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=ANN RHEUM DIS：随机I期研究中重复注射dapirolizumab pegol耐受性良好，并伴随系统性红斑狼疮疾病活动改善和全血转录组学特征改变, objectType=article, longId=108003, objectId=15611080035b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15611080035b, replyNumber=0, likeNumber=41, createdTime=2017-08-09, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15611080035b, moduleTitle=ANN RHEUM DIS：随机I期研究中重复注射dapirolizumab pegol耐受性良好，并伴随系统性红斑狼疮疾病活动改善和全血转录组学特征改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15611080035b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PEG

2020-05-29

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期

2020-01-29

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-01-10

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败

2019-10-22

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点

2019-10-19

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复

2019-10-05

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？

2019-09-28

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用

2019-06-12

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2019-06-04

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Tissue Eng Part A：纳米图案化的PEG-GelMA-HA水凝胶增强牙髓干细胞的软骨形成分化

2019-05-21

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据

2019-04-09

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症

2019-03-06

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

DAA治愈慢性丙型肝炎PEG-IFN联合利巴韦林抗病毒过程中并发重度自身免疫性溶血性贫血1例

2019-03-02

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意

2019-02-21

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据

2019-01-31

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著

2018-12-27

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

【临床治愈，一生一试】PegIFNα-2a助乙肝患者获得最佳治疗目标

2018-12-05

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

2018 APEG共识指南：儿童和青少年应用双磷酸盐治疗

2018-03-12

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Int J Nanomed：oMCN@PEG可作为高效抗癌药物递送载体使用

2017-12-05

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Oncol Lett：LncRNA PEG10过表达可促进鳞状细胞癌的进展

2017-10-01

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

ANN RHEUM DIS：随机I期研究中重复注射dapirolizumab pegol耐受性良好，并伴随系统性红斑狼疮疾病活动改善和全血转录组学特征改变

2017-08-09

科室
- - 订阅+
  - 更多科室
工具
服务